Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ?2 years who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib Sulfate was developed by Array Biopharma Inc.
The API has now reached off-patent status, after being launched in 2020.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Selumetinib Sulfate and many others, contact info@pharmacheminvestor.com